Clinical Trials
Printable Version   Email to a friend

Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 9, 2007 - Neose Technologies, Inc. (NasdaqGM:NTEC) announced today that it will present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference held at the Mandarin Oriental Hotel in New York City from July 10-12, 2007. The Company's presentation is scheduled for 2:00 p.m. (EDT) on Tuesday, July 10, 2007. The presentation will be webcast live and available for replay via the following link:

http://www.wsw.com/webcast/ceut6/ntec/

The webcast will also be available on the Investor Relations/Audio Archives page of the Company's website, www.neose.com.

Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market, on its own and through strategic partnerships. The lead candidates in its pipeline, NE-180 for use in the treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure and GlycoPEG-GCSF for chemotherapy-induced neutropenia, target markets with aggregate sales in excess of $15 billion.

For more information, please visit www.neose.com.

Contact

Neose Technologies, Inc.
A. Brian Davis
Sr. Vice President and Chief Financial Officer
or
Barbara Krauter
Manager, Corporate Communications
215-315-9000

Latest Clinical Trial Results...

Clinical Trial Results Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec

More News Resources


MedNotes
Advertisement